MX2022000709A - Regimenes de tratamiento con dexmedetomidina no sedante. - Google Patents

Regimenes de tratamiento con dexmedetomidina no sedante.

Info

Publication number
MX2022000709A
MX2022000709A MX2022000709A MX2022000709A MX2022000709A MX 2022000709 A MX2022000709 A MX 2022000709A MX 2022000709 A MX2022000709 A MX 2022000709A MX 2022000709 A MX2022000709 A MX 2022000709A MX 2022000709 A MX2022000709 A MX 2022000709A
Authority
MX
Mexico
Prior art keywords
sedating
treatment regimens
dexmedetomidine
dexmedetomidine treatment
disclosed
Prior art date
Application number
MX2022000709A
Other languages
English (en)
Inventor
Frank Yocca
Vasukumar Kakumanu
David Christian Hanley
Scott David Barnhart
Chetan Dalpatbhai Lathia
Lavanya Rajachandran
Robert Risinger
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MX2022000709A publication Critical patent/MX2022000709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen métodos para administrar dosis relativamente altas de dexmedetomidina o una sal farmacéuticamente aceptable de esta a un sujeto humano, sin inducir también una sedación significativa. Los métodos descritos son particularmente adecuados para el tratamiento de la agitación, especialmente cuando se asocia con enfermedades neurodegenerativas y/o neuropsiquiátricas tales como la esquizofrenia, la enfermedad bipolar, tal como el trastorno bipolar o la manía, la demencia, la depresión o el delirio.
MX2022000709A 2019-07-19 2020-07-17 Regimenes de tratamiento con dexmedetomidina no sedante. MX2022000709A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962876371P 2019-07-19 2019-07-19
US201962877056P 2019-07-22 2019-07-22
US201962943022P 2019-12-03 2019-12-03
US202062963769P 2020-01-21 2020-01-21
US202062970411P 2020-02-05 2020-02-05
US202062977554P 2020-02-17 2020-02-17
US202063037759P 2020-06-11 2020-06-11
PCT/US2020/042618 WO2021016112A2 (en) 2019-07-19 2020-07-17 Non-sedating dexmedetomidine treatment regimens

Publications (1)

Publication Number Publication Date
MX2022000709A true MX2022000709A (es) 2022-05-19

Family

ID=74193768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000709A MX2022000709A (es) 2019-07-19 2020-07-17 Regimenes de tratamiento con dexmedetomidina no sedante.

Country Status (12)

Country Link
US (3) US20240024288A1 (es)
EP (1) EP3999058A4 (es)
JP (1) JP2022540706A (es)
KR (1) KR20220049526A (es)
CN (1) CN114375191A (es)
AU (1) AU2020316013A1 (es)
BR (1) BR112022000992A2 (es)
CA (1) CA3145388A1 (es)
IL (1) IL289735A (es)
MX (1) MX2022000709A (es)
TW (1) TW202116304A (es)
WO (1) WO2021016112A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240031326A (ko) 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
CA3103431A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP4271376A1 (en) * 2021-01-04 2023-11-08 BioXcel Therapeutics, Inc. Dexmedetomidine treatment regimens
EP4297871A1 (en) * 2021-02-26 2024-01-03 BioXcel Therapeutics, Inc. Methods and compositions for treating agitation
WO2023278824A1 (en) * 2021-07-02 2023-01-05 Bioxcel Therapeutics, Inc. Methods for treating depressive states
WO2024055042A1 (en) * 2022-09-11 2024-03-14 Bioxcel Therapeutics, Inc. Methods for treating agitation in community settings
US11806334B1 (en) * 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
US4839170A (en) 1985-10-01 1989-06-13 Survival Technology, Inc. Protein absorption enhancing agents
US4767789A (en) 1986-10-21 1988-08-30 American Home Products Corporation (Del.) Spray dried acetaminophen
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4760093A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems San Pulmonale abgabe von aktiven fragmenten des parathormons
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
EP0681601B1 (en) 1993-11-29 1999-02-17 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5508367A (en) 1993-11-29 1996-04-16 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5395907A (en) 1993-11-29 1995-03-07 Adhesive Research, Inc. Water-soluble pressure sensitive adhesive
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US5731387A (en) 1994-07-11 1998-03-24 Adhesives Research, Inc. Ionically-crosslinked water-absorbent graft copolymer
US5726250A (en) 1994-07-11 1998-03-10 Adhesives Research, Inc. Covalently crosslinked water-absorbent graft copolymer
US6726928B2 (en) 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5700873A (en) 1995-03-07 1997-12-23 Adhesives Research, Inc. Method of preparation of water-soluble copolymer
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9616672D0 (en) 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
KR20000070375A (ko) 1997-02-21 2000-11-25 에드워드 엘. 데이지 압력 민감성 접착제 약물 경피 전달 시스템과 이에 사용되는압력 민감성 접착제
US6239228B1 (en) 1997-02-21 2001-05-29 Adhesives Research, Inc. Pressure sensitive adhesive containing macromer having repeat hydrophilic moieties
US5951999A (en) 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1001748B1 (en) 1997-07-25 2006-04-19 Alpex Pharma S.A. A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
JP4237405B2 (ja) 1998-03-09 2009-03-11 シーマ・ラブス、インコーポレイテッド 集成体
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
US6807965B1 (en) 1998-06-03 2004-10-26 Scott Laboratories, Inc. Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures
US7565905B2 (en) 1998-06-03 2009-07-28 Scott Laboratories, Inc. Apparatuses and methods for automatically assessing and monitoring a patient's responsiveness
AU2005201500B2 (en) 1998-06-03 2007-01-04 Scott Laboratories, Inc. Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
DE19940740A1 (de) 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
US6984207B1 (en) 1999-09-14 2006-01-10 Hoana Medical, Inc. Passive physiological monitoring (P2M) system
CA2324967A1 (en) 2000-11-01 2002-05-01 3816133 Canada Inc. System for monitoring patients with alzheimer's disease or related dementia
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
AU7323001A (en) 2000-07-07 2002-01-21 Av Topchiev Inst Petrochemical Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020192287A1 (en) 2000-11-09 2002-12-19 Mooney Mark T. Extrudable compositions for topical or transdermal drug delivery
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
WO2002089794A1 (en) 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
US20030083822A2 (en) 2001-05-15 2003-05-01 Psychogenics, Inc. Systems and methods for monitoring behavior informatics
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
EP1549305B1 (en) 2002-10-08 2009-04-22 Allergan, Inc. Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of morbus alzheimer and morbus parkinson
US20040156894A1 (en) 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
EP1663178A1 (en) 2003-05-28 2006-06-07 MonoSolRX, LLC Films based on poly(ethylene oxide), and drug delivery systems made thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
EP1680079A4 (en) 2003-10-24 2008-01-02 Adhesives Res Inc QUICKLY FILING FILMS FOR THE DISTRIBUTION OF PHARMACEUTICAL OR COSMETIC AGENTS
US9248146B2 (en) 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
GB0403808D0 (en) 2004-02-20 2004-03-24 Bioprogress Technology Ltd Films for use as dosage forms
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
US7972621B2 (en) 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US20060058590A1 (en) 2004-08-24 2006-03-16 Shaw Geoffrey M Method and system for assaying agitation
US20060058700A1 (en) 2004-08-26 2006-03-16 Marro Dominic P Patient sedation monitor
AU2005286733B2 (en) 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1871219A4 (en) 2005-02-22 2011-06-01 Health Smart Ltd METHODS AND SYSTEMS FOR PSYCHOPHYSIOLOGICAL AND PHYSIOLOGICAL CONTROL AND USES THEREOF
US20060199805A1 (en) 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20090076156A1 (en) 2005-07-18 2009-03-19 Masud Husain Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
US20070106126A1 (en) 2005-09-30 2007-05-10 Mannheimer Paul D Patient monitoring alarm escalation system and method
WO2007041697A2 (en) 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
PT1986642E (pt) 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
US7630758B2 (en) 2006-06-22 2009-12-08 General Electric Company Separation of natural and drug-induced sleep of a subject
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
EP2063864A4 (en) 2006-09-20 2012-03-14 Monosol Rx Llc EDIBLE WATER-SOLUBLE FILM CONTAINING FLAVOR-REDUCING AGENT
US8157730B2 (en) 2006-12-19 2012-04-17 Valencell, Inc. Physiological and environmental monitoring systems and methods
US20080153808A1 (en) 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8568777B2 (en) 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
CN101801346A (zh) 2007-05-10 2010-08-11 诺瓦德尔药品公司 抗失眠症组合物及方法
US20090099480A1 (en) 2007-05-24 2009-04-16 Peter Salgo System and method for patient monitoring
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
MX2010003928A (es) 2007-10-11 2010-09-10 Philip Morris Prod Producto de tabaco sin humo.
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
PE20091084A1 (es) 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
CN101496801A (zh) 2008-02-02 2009-08-05 四川百利药业有限责任公司 右旋美托咪定及其药用盐的用途
EP2252290B1 (en) 2008-02-15 2017-11-29 Bone Therapeutics S.A. Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
JP5547096B2 (ja) 2008-02-28 2014-07-09 アール．ピー． シェーラー テクノロジーズ エルエルシー 多型を最小化する方法
US20190216389A1 (en) 2008-04-07 2019-07-18 Christopher Scheib Method and system for analyzing a series of electroencephalogram (eeg) signals during altered brain states
US20090275853A1 (en) 2008-04-30 2009-11-05 The General Electric Company Method and apparatus for monitoring physiological state of a subject
US8882684B2 (en) 2008-05-12 2014-11-11 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
JP2012502915A (ja) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド てんかんを治療する組成物及び方法
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8470546B2 (en) 2008-11-25 2013-06-25 Albert Einstein College Of Medicine Of Yeshiva University Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus-Noradrenergic system
EP2370136A4 (en) 2008-12-01 2015-12-30 Map Pharmaceuticals Inc INHALATIVE RELEASE PROCEDURES AND DEVICES
US8282954B2 (en) 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
TR200903014A1 (tr) 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
EP2429521B1 (en) 2009-05-15 2017-10-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
RU2012133969A (ru) 2010-01-08 2014-02-20 Рекро Фарма, Инк. Локальные трансдермальные композиции дексмедетомидина и способы их применения
WO2011109716A2 (en) 2010-03-04 2011-09-09 Neumitra LLC Devices and methods for treating psychological disorders
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
US20130029989A1 (en) 2010-04-15 2013-01-31 The Royal Institution For The Advancement Of Learning/Mcgill University Topical treatments for pain
US9572773B2 (en) 2010-04-26 2017-02-21 Novartis A.G. Layered drug delivery device
US20110290694A1 (en) 2010-05-27 2011-12-01 Monosol Rx, Llc Oral film dosage form having indicia thereon
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US10137245B2 (en) 2010-08-17 2018-11-27 University Of Florida Research Foundation, Inc. Central site photoplethysmography, medication administration, and safety
CA2815568C (en) 2010-09-23 2018-10-09 Monosolrx Llc Method and system for forming a pharmaceutical product directly onto a packaging surface
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20140163080A1 (en) * 2011-02-03 2014-06-12 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
US8241661B1 (en) 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
US8703697B2 (en) 2011-06-24 2014-04-22 Luc QUINTIN Method for treating early severe diffuse acute respiratory distress syndrome
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
EP3406247A1 (en) 2011-12-11 2018-11-28 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
JP5921928B2 (ja) 2012-03-28 2016-05-24 テルモ株式会社 既希釈デクスメデトミジン製剤
CN102657635B (zh) 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
US10130766B1 (en) 2012-08-08 2018-11-20 Neurowave Systems Inc. Intelligent pharmaceutical delivery system with automatic shutoff and method of using
SI2719376T1 (sl) 2012-10-12 2015-06-30 Omya International Ag Gastrointestinalna zdravilna formulacija in razdeljevalni sistem in njen naäśin priprave z uporabo funkcionaliziranega kalcijevega karbonata
US20140180160A1 (en) 2012-10-12 2014-06-26 Emery N. Brown System and method for monitoring and controlling a state of a patient during and after administration of anesthetic compound
ES2659271T3 (es) 2012-10-15 2018-03-14 Orion Corporation Método veterinario para aliviar la aversión al ruido
GB2510321B (en) 2012-11-12 2018-01-31 Biosurgical S L Agitation apparatus
WO2014116770A1 (en) 2013-01-23 2014-07-31 Arx, Llc Production of unit dose constructs
CN105228652A (zh) 2013-02-21 2016-01-06 罗契斯特大学 评价全脑血管旁路径的废弃物清除功能的方法以及基于这种方法治疗神经退化性病症的方法
US20140275194A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Films and drug delivery systems for rizatriptan
US20140261990A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Multi-layer films having uniform content
US9346601B2 (en) 2013-03-15 2016-05-24 Monosol Rx, Llc Reduction in stress cracking of films
US9303918B2 (en) 2013-03-15 2016-04-05 Monosol Rx, Llc Process for drying a wet film with control of loss on drying
WO2014144365A1 (en) 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
EP2976404B1 (en) 2013-03-22 2021-06-30 Adhesives Research, Inc. Hydrophilic adhesives and tapes and devices containing the same
EP2988666A1 (en) 2013-04-23 2016-03-02 The General Hospital Corporation System and method for monitoring anesthesia and sedation using measures of brain coherence and synchrony
WO2014176441A1 (en) 2013-04-24 2014-10-30 The General Hospital Corporation System and method for monitoring level of dexmedatomidine-induced sedation
WO2014176444A1 (en) 2013-04-24 2014-10-30 The General Hospital Corporation System and method for estimating high time-frequency resolution eeg spectrograms to monitor patient state
CN103284945A (zh) 2013-06-03 2013-09-11 四川百利药业有限责任公司 一种预充式盐酸右美托咪定注射液的制备方法
JP6453319B2 (ja) 2013-06-04 2019-01-16 モノソル リミテッド ライアビリティ カンパニー 水溶性フィルムシール溶液、関連する方法、および関連する物品
US10314503B2 (en) 2013-06-27 2019-06-11 The General Hospital Corporation Systems and methods for tracking non-stationary spectral structure and dynamics in physiological data
US10383574B2 (en) 2013-06-28 2019-08-20 The General Hospital Corporation Systems and methods to infer brain state during burst suppression
US10602978B2 (en) 2013-09-13 2020-03-31 The General Hospital Corporation Systems and methods for improved brain monitoring during general anesthesia and sedation
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
EP3054931B1 (en) 2013-10-07 2020-12-23 Teikoku Pharma USA, Inc. Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions
EP3054934A4 (en) 2013-10-07 2017-04-05 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
JP6188933B2 (ja) * 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物
WO2015069778A1 (en) 2013-11-05 2015-05-14 The General Hospital Corporation System and method for determining neural states from physiological measurements
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
WO2015093503A1 (ja) * 2013-12-18 2015-06-25 丸石製薬株式会社 含水型貼付剤
US20170274174A1 (en) 2014-08-22 2017-09-28 The General Hospital Corporation System and method for administering, monitoring and controlling biomimetic sleep
US20170273611A1 (en) 2014-08-22 2017-09-28 The General Hospital Corporation Systems and methods for discovery and characterization of neuroactive drugs
US20170231556A1 (en) 2014-08-22 2017-08-17 The General Hospital Corporation Systems and methods for predicting arousal to consciousness during general anesthesia and sedation
CN104161760A (zh) 2014-09-01 2014-11-26 西北农林科技大学 一种貉用复合麻醉剂及其制备方法和应用
MA41689A (fr) 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
WO2016061554A1 (en) 2014-10-16 2016-04-21 Bioxcel Corporation Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
FI127534B (en) 2014-11-10 2018-08-31 Vetcare Oy Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions
WO2016089997A1 (en) 2014-12-02 2016-06-09 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
JP2016154598A (ja) 2015-02-23 2016-09-01 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
CN104784174A (zh) 2015-03-06 2015-07-22 北京大学第一医院 右美托咪定的药物新用途
US11160901B2 (en) 2015-04-10 2021-11-02 Tricol Biomedical, Inc. Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field
CN106038538A (zh) 2015-04-17 2016-10-26 江苏恒瑞医药股份有限公司 一种右美托咪定的预混合制剂
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20160374588A1 (en) 2015-06-24 2016-12-29 Microsoft Technology Licensing, Llc Monitoring hydration based on galvanic skin response
CN105168122B (zh) 2015-09-24 2018-11-27 辰欣药业股份有限公司 一种盐酸右美托咪定注射液及其制备工艺
US10632043B2 (en) 2015-11-11 2020-04-28 Aurobindo Pharma Ltd Premix formulation for parenteral use and packaging thereof
US20170128421A1 (en) 2015-11-11 2017-05-11 Siva Prasad Reddy Sura Premix formulation for parenteral use and packaging thereof
EP3400050B1 (en) 2016-01-04 2020-12-23 Jurox Pty. Ltd. Drug release device and use
CN105534891A (zh) 2016-01-18 2016-05-04 南京正科医药股份有限公司 一种盐酸右美托咪定注射液
US9949934B1 (en) 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
CN107412152B (zh) 2016-05-24 2020-12-04 海南合瑞制药股份有限公司 一种盐酸右美托咪定注射液组合物
WO2017213977A1 (en) 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
CN105997955B (zh) 2016-06-28 2017-09-12 力品药业（厦门）有限公司 一种帕洛诺司琼口腔膜剂及其制备方法
RU2635532C1 (ru) 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
EP4241759A1 (en) 2016-10-12 2023-09-13 PS Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
JP7219712B2 (ja) 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
JP6968184B2 (ja) 2016-10-25 2021-11-17 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 速崩壊多層錠のための異なる密度の組成物
JP2019534288A (ja) 2016-10-31 2019-11-28 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
CN106727524A (zh) 2016-11-08 2017-05-31 叶茂 一种药物组合物及其应用
CN106539778A (zh) 2016-12-08 2017-03-29 武汉大学 一种小儿麻醉术前含服口腔泡腾片及其制备方法
CN106727443A (zh) 2016-12-08 2017-05-31 武汉大学 一种小儿麻醉术前镇静的隐形鼻贴制剂及其制备方法
RU2759726C2 (ru) 2016-12-13 2021-11-17 Орион Корпорейшн Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак
WO2018116202A1 (en) 2016-12-20 2018-06-28 Azista Industries Pvt Ltd Stabilized mouth freshener strips
KR20240031326A (ko) 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
JP2020510675A (ja) 2017-03-07 2020-04-09 チャイルズ， マークＣＨＩＬＤＳ， Ｍａｒｃ ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防
CN107693485A (zh) 2017-04-24 2018-02-16 重庆医科大学附属儿童医院 一种用于麻醉的滴鼻液及其制备方法
CN107137399A (zh) 2017-04-24 2017-09-08 徐颖 一种用于麻醉的舌下片及其制备方法
CN107412204A (zh) 2017-04-24 2017-12-01 重庆医科大学附属儿童医院 一种用于麻醉的干粉吸入剂及其制备方法
CN107028880A (zh) 2017-06-09 2017-08-11 安徽赛诺制药有限公司 一种盐酸右美托咪定注射液的生产工艺
EP3668488A4 (en) 2017-08-15 2021-03-24 The Board of Trustees of the Leland Stanford Junior University POLYMERIC PERFLUOROCARBON NANOEMULSIONS FOR ULTRASONIC DRUG RELEASE
CA3071552A1 (en) 2017-08-20 2019-02-28 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
JP7108267B2 (ja) 2017-08-30 2022-07-28 日本電気株式会社 生体情報処理システム、生体情報処理方法、及びコンピュータプログラム
US11857334B2 (en) 2017-10-04 2024-01-02 The General Hospital Corporation Systems and methods for monitoring a subject under the influence of drugs
WO2019073927A1 (ja) 2017-10-10 2019-04-18 日本電気株式会社 生体情報処理システム、生体情報処理方法、および生体情報処理プログラム記録媒体
US20190216345A1 (en) 2017-10-18 2019-07-18 Christoper Scheib Method and system for monitoring and displaying physiological conditions
US11147459B2 (en) 2018-01-05 2021-10-19 CareBand Inc. Wearable electronic device and system for tracking location and identifying changes in salient indicators of patient health
US11406316B2 (en) 2018-02-14 2022-08-09 Cerenion Oy Apparatus and method for electroencephalographic measurement
AU2019229784A1 (en) 2018-03-08 2020-08-13 Catalent U.K. Swindon Zydis Limited Process to reduce endotoxin in gelatin
KR20190109310A (ko) 2018-03-15 2019-09-25 주식회사 바이오홀딩스 레반을 함유하는 염증성 질환 치료용 경비투여형 스프레이 제제
CN108498469A (zh) 2018-05-30 2018-09-07 宁波蒙曼生物科技有限公司 盐酸右美托咪定冻干粉及其制备方法
US20210267944A1 (en) 2018-06-27 2021-09-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CA3103431A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CN110893186A (zh) 2018-09-12 2020-03-20 宜昌人福药业有限责任公司 一种药物组合物及其制备方法和用途
JP2019048091A (ja) 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
KR102183744B1 (ko) 2018-11-26 2020-11-27 연세대학교 산학협력단 섬망 발병 위험도의 예측 방법 및 이를 이용한 디바이스
CN109620802A (zh) 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN111481506B (zh) 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
US10900762B2 (en) 2019-02-21 2021-01-26 Aob Products Company Ammunition press and components thereof
CN112107544A (zh) 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN112138250B (zh) 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CA3154659A1 (en) 2019-09-18 2021-03-25 Bioxcel Therapeutics, Inc. Systems and methods for detection and prevention of emergence of agitation
CA3167994A1 (en) 2020-02-14 2021-08-19 Bioxcel Therapeutics, Inc. Systems and methods for detection and prevention of emergence of agitation
EP4225305A1 (en) 2020-10-08 2023-08-16 Bioxcel Therapeutics, Inc. Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
EP4271376A1 (en) 2021-01-04 2023-11-08 BioXcel Therapeutics, Inc. Dexmedetomidine treatment regimens
EP4297871A1 (en) 2021-02-26 2024-01-03 BioXcel Therapeutics, Inc. Methods and compositions for treating agitation

Also Published As

Publication number Publication date
CN114375191A (zh) 2022-04-19
EP3999058A2 (en) 2022-05-25
IL289735A (en) 2022-03-01
BR112022000992A2 (pt) 2022-06-14
WO2021016112A2 (en) 2021-01-28
WO2021016112A3 (en) 2021-04-08
TW202116304A (zh) 2021-05-01
US20230118091A1 (en) 2023-04-20
JP2022540706A (ja) 2022-09-16
EP3999058A4 (en) 2023-05-03
CA3145388A1 (en) 2021-01-28
KR20220049526A (ko) 2022-04-21
US11890272B2 (en) 2024-02-06
AU2020316013A1 (en) 2022-02-17
US20230338339A1 (en) 2023-10-26
US20240024288A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2022000709A (es) Regimenes de tratamiento con dexmedetomidina no sedante.
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2018006223A (es) Moduladores de ror-gamma.
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
SG10201811204RA (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2017012430A (es) Formas solvatadas de un inhibidor de tirosina quinasa de bruton.
MX2021002321A (es) Nuevos metodos.
PH12017500977A1 (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112023013033A2 (pt) Regimes de tratamento com dexmedetomidina
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
MX2018000947A (es) Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2.
MX2019001320A (es) Composicion y uso de un peptido.
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine